Shahzeb Khan
@ShahzebKhanMD
Followers
3,334
Following
584
Media
55
Statuses
819
Cardiologist at @Bswhealth •Alum @DukeHeartCenter , @CookCtyHealth , @RushGradCollege , @UMMCnews •Founder of @R_C_O_P
Dallas, TX
Joined March 2013
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
namjoon
• 329630 Tweets
Linkin Park
• 149707 Tweets
Adalet
• 120089 Tweets
For Asia
• 101222 Tweets
Chester
• 77529 Tweets
علي النبي
• 73352 Tweets
BTS PAVED THE WAY
• 67997 Tweets
Hayırlı Cumalar
• 46808 Tweets
Engin Polat
• 46126 Tweets
サブスク解禁
• 44824 Tweets
#BAEKHYUN_PINEAPPLESLICE
• 38235 Tweets
エイリアン
• 31169 Tweets
#يوم_الجمعه
• 29095 Tweets
資さんうどん
• 26808 Tweets
知的レベル
• 25435 Tweets
すかいらーく
• 24195 Tweets
アストロボット
• 20031 Tweets
ちいかわ寿司
• 19926 Tweets
ベイマックス
• 14946 Tweets
大阪府警
• 12985 Tweets
MEW LOVE IN THE AIR
• 12234 Tweets
フリーランスの田中
• 10962 Tweets
TILFF X UPPOOM
• 10927 Tweets
ロムルス
• 10418 Tweets
神ちゃん
• 10044 Tweets
Incredibly excited and honored to match in Cardiology at
@DukeHeartCenter
. Extremely grateful to
@JavedButler1
@SJGreene_md
@FudimMarat
@RichKrasuskiMD
@ErinMichos
@ambarish4786
@RamiDoukky
and many others for all the great help during the application process.
44
5
276
SGLT-2 inhibitors in Heart Failure with Preserved Ejection Fraction: Reasons for Optimism ‼️
✅Targets multiple processes simulatenously which may be implicated in HFpEF
✅Placebo event rates in EMPA-REG Outcome similar to previous HFpEF trials
1
48
162
Suggested approach of using SGLT-2 inhibitors or GLP-1 RA in different clinical scenarios from the state of the art review published in
@CircAHA
today
3
51
131
Predicting and Preventing Heart Failure in Type 2 Diabetes
📝 in
@TheLancetEndo
@ambarish4786
@SubodhVermaMD
@DLBHATTMD
@kershawpatel
0
50
128
Editorial in
@JACCJournals
with
@JavedButler1
.
Treatment is Good, Prevention is Better: Heart Failure Prevention for All
7
27
120
Should etiology of heart failure be assessed more systematically in a standardized fashion in RCTs, or not at all, or what we have currently is good enough ?! Our editorial in
@ESC_Journals
discusses the assessment of etiology in HF.
@JavedButler1
0
20
109
Our 📑 in
@ESC_Journals
highlights
📌 ⬆️ Heterogeneity in reporting of kidney function and kidney outcomes in large RCTs
📌Need for stakeholders to draft a consensus solution
📌 Standardization of kidney outcomes, definitions and stats modelling, may help compare trial 📈
3
23
92
Practical and Evidence-Based Approaches to In-Hospital Decongestion for Heart Failure:Are We There Yet
Editorial comment in
@JACCJournals
on BLUSHED-AHF pilot trial
Editorial:
BLUSHED-AHF:
Grateful to
@SJGreene_md
for opportunity
1
29
91
Results from combined analysis of FAIR-HF and CONFIRM-HF
📌Pts receiving FCM had ⬆️⬆️ likelihood of >5,10 and 15 points improvement in KCCQ at week 12
📌These benefits persisted in >75% of the pts at week 24
🔑IV FCM improves QOL with sustained benefits
11
26
87
Mechanisms of current therapeutic strategies for heart failure: more questions than answers ?
1
27
83
New analysis of EMPEROR-Reduced in
@ESC_Journals
🔑 Empagliflozin reduces CV death/HF hospitalization across spectrum of baseline health
🔑 Empagliflozin improves health status across various domains
🔑 Benefits sustained during long term f/up
0
25
83
The need for increased pragmatism in cardiovascular clinical trials
@NatRevCardiol
@ShariqUsman_
@JavedButler1
@SJGreene_md
@hvanspall
@robmentz
@FudimMarat
@ambarish4786
@DukeCardFellows
@DukeHeartCenter
@texhern
@manesh_patelMD
@gcfmd
@ziadalinyc
2
18
83
Results of EMPEROR-Reduced By Baseline Diabetes Status Published in
@CircAHA
today.
Favorable heart failure and renal effects of empagliflozin were consistent in patients with and without T2DM, and across spectrum of A1C.
1
22
76
You know you are at the best place for
#cardiologyfellowship
when incredible faculty
@DukeHeartCenter
take you to
@dukebasketball
matches on weekend after a great week of rounding on complex structural/congenital heart patients. Big shoutout to
@RichKrasuskiMD
for being the best
3
3
76
State of the Art Review in
@CircAHA
regarding GLP-1 RA and Heart Failure.
•No clear benefit on HF outcomes
•Possible safety issues in HFrEF
•May benefit HFpEF
•Dedicated trials for HFrEF and HFpEF needed
5
26
74
New 📝 in
@JAMA_current
where we propose
📌Reporting of stability of observed changes in PRO
📌Stability of response ➡️ how many who initially improved remained ⬆️ rather than reverting to neutral or ⬇️
📌Comparing PRO over time can ✅ Rx benefits are robust
@JavedButler1
2
10
74
Comparison of Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in HFrEF patients with and without T2DM. New data from PROVE-HF in
@JACCJournals
under the great mentorship of
@JavedButler1
and
@JJheart_doc
0
14
72
📌 Our editorial in
@JACCJournals
regarding serial NT-proBNP measurements and implementation of GDMT.
📌 Potential use of NT-proBNP as a virtual physical exam
Comment to the excellent 📝 by
@MichaelFueryMD
,
@yaleHFdoc
et al:
2
15
74
Honored to present at
#ADA
on socio-economics of heart failure with this amazing group
@drpmcampbell
@HeartDocSadiya
. Special thanks to
@hvanspall
and
@kaulcsmc
for the amazing opportunity
@DukeHeartCenter
1
6
69
Our comprehensive meta-analysis of 22 studies suggests imp diagnostic and prognostic value of LA function in HFpEF
All measures of volumetric LA function ⬇️ in HFpEF
⬇️ LA reservoir strain ⬆️ risk of HFH/all cause mortality
2
13
67
Minimal Clinically Important Difference for Six Minute Walk Test in Patients with HFrEF and Iron Deficiency: Pooled Analysis of FAIR-HF and CONFIRM-HF trials
@JavedButler1
@JCardFail
3
18
63
Baseline characteristics of the much awaited trial EMPEROR-Preserved are out now in
@ESC_Journals
@JavedButler1
@Filippatos
@MarcoMetra
0
14
59
In this review published in
@JAMACardio
, we highlight the potential role and limitations of eGFR slope assessment in CV trials.
@JavedButler1
@IzzaShahid_
@mvaduganathan
@SJGreene_md
@hvanspall
@FudimMarat
@gcfmd
@JTLLERGO
@khurramn1
@DukeHeartCenter
0
18
59
Our fun paper “Kardashian Index of Cardiologists” published in
@JACCJournals
. K index is the correlation b/w the no of citations for a scientist and no of followers they have on twitter. Intermingling of academic research/social media
1
16
58
📌 ⬆️⬆️⬆️ burden of HF related ☠️ in young adults
📌 Black adults have ~3 times ⬆️ rate
📌 Significant geographic variation in ☠️
🎯Urgent action needed to address this concerning trend & ⬇️ disparities
🎯 Early Dx and implementation of GDMT 🔑
See
3
14
56
Great study in
@JACCJournals
led by
@MattSegar
and
@ambarish4786
regarding prevalence and implications of DM with cardiomyopathy in the community. Targeted prescription of effective Rx needed to ⬇️ risk of HF among such patients
0
12
55
Conducting Clinical Trials During and After the COVID-19 Pandemic: An Expert Consensus Position Paper from the HFA of the
@escardio
@JavedButler1
@MarcoMetra
@AdriaanVoors
@jteerlinkmd
@Filippatos
@JBauersachsMD
@BiykemB
@texhern
@ehj_ed
0
13
50
Joint Position Paper of Heart Failure Association of the
@escardio
and Chinese HF Association regarding management of heart failure patients with COVID-19. An excellent overview based on available data /personal experiences led by
@MarcoMetra
🔥:
2
21
45
Rigorous, systematic and standardized framework needed for adequate comorbidity reporting and ⬆️ recruitment of multi-morbid HF pts.
Many thanks to
@Ayman__Tahhan
@mvaduganathan
@JavedButler1
for letting me contribute in this imp paper
0
13
43
Our new meta analysis regarding FCM for the treatment of iron deficient heart failure patients published in
@ESC_Journals
@HFA_President
No benefit on all-cause or CV mortality but reduces HF/CV hospitalizations
0
5
42
Our latest perspective in
@CircOutcomes
on orphan drug development using examples of tafamidis and evolocumab. Current pathways ⬇️ evidentiary bar and generally priced ⬆️⬆️ due to marketing incentives. Pricing of orphan drugs needs regular re-evaluation
1
11
42
Low Na diet is a common order that we put in. Does it really improve pt outcomes ? Our editorial “Salt, no salt or less salt for HF pts” discusses pros and cons. More research needed for optimum🧂intake.
@JavedButler1
@amjmed
3
11
39
📌Kidney Involvement in Transthyretin Cardiac Amyloidosis
✅Role of UACR and Need for Further Evidence Generation
Editorial:
Original Article:
0
12
40
Natriuretic Peptide Levels and Risk of Cardiovascular Versus Non-Cardiovascular Events in HFrEF-Insights from the PARADIGM-HF and ATMOSPHERE Trials
0
5
39
Extremely well deserved- UTSW is lucky to have you. You will be a ⭐️ there.
Thrilled to match at my
#1
choice: The UT Southwestern Internal Medicine-Cardiology PSTP track!
Wouldn't have been possible without my mentors
@ShahzebKhanMD
and
@JavedButler1
Excited to join the
@UTSWInternalMed
family!!
@UTSW_IMResRsrch
@utswheart
@UTSWNews
#Match2023
25
7
328
1
0
35
Predicting and Preventing Heart Failure in Type 2 Diabetes Mellitus
@ambarish4786
@DLBHATTMD
@SubodhVermaMD
@kershawpatel
@UTSWNews
@DukeHeartCenter
@TheLancet
Out now in
@TheLancetEndo
1
5
34
PROGRESS-HF Phase 2 Trial out now in
@JCardFail
. The trial evaluated the effects of elamipretide, a novel mitochondrial modulating agent, on LV function in HFrEF patients. Special thanks to
@JavedButler1
and
@Filippatos
.
See results below
3
12
34
Excited to get the award at the
@SCMRorg
conference in Orlando for paper published in
@journalofCMR
. Special thx to Dr Manning and
@khosafaisal
.
#SCMR2020
#whyCMR
#cvImaging
4
3
35
📌 Rx of iron deficient HFrEF with IV iron ⬇️ HF 🏥 and CV ☠️
📌95% CI crossed upper limit of 1 in the Bayesian Prediction Model ➡️ some uncertainty
📌Nominally consistent across subgroups
📌 📝 HEART-FID and FAIR-HF2 awaited
0
10
35
📝 in
@ESC_Journals
from EMP-Reduced
📌 Benefits of empa consistent across all BMI groups
📌 Weight loss led to ⬆️ all cause mortality in both groups
📌Distinction b/w intentional vs unintentional weight loss is imp.
1
6
31
Accelerometer versus other activity measures in heart failure with preserved ejection fraction: VITALITY-HFpEF Sub-Study
@JavedButler1
@lamcardio
@CVC_UAlberta
@ESC_Journals
@FudimMarat
@DukeHeartCenter
@ValleAlfonso
@JTLLERGO
0
6
30
@CircAHA
GFRW 2020
•All fields except orthopedics had higher proportion of women trainees than ❤️
•Only 21% of general ❤️ trainees were women
•Even ⬇️ in IC and EP
•PCCM & ❤️ the most male dominated IM spec
•Peds ❤️trainees were 50% women
0
17
31
In this article published today in JAMA open, we discuss spin (manipulation of language) in CV RCTs
@drjohnm
@RamiDoukky
@TariqJamalSidd1
@safinmc
@RichKrasuskiMD
0
8
28
Empagliflozin for the treatment of HFpEF: Prophecy fulfilled
Great for patients with HFpEF to finally have a tx which improves outcomes. Eagerly await EMPEROR-PRESERVED at ESC
Kudos to the leadership
@JavedButler1
@Filippatos
@FaiezZANNAD
#StefanAnker
SGLT-2 inhibitors in Heart Failure with Preserved Ejection Fraction: Reasons for Optimism ‼️
✅Targets multiple processes simulatenously which may be implicated in HFpEF
✅Placebo event rates in EMPA-REG Outcome similar to previous HFpEF trials
1
48
162
1
5
27
Really looking forward to this session at
#CVCT2021
on cheaper, faster and more efficient trials: is pragmatic the solution. Tune in at
#CVCT2021
to hear more:
@hvanspall
@CVCTForum
@FaiezZANNAD
@JavedButler1
@docbhardwaj
0
8
26
Insights from VITALITY-HFpEF
📌8.3 points represents MCID for improvement for KCCQ-Physical Limitation Score✅✅
📌Any degree of worsening in KCCQ-PLS from baseline is imp‼️
📌These threshols from pre-specified/blinded analysis have 🔑 implications for future HFpEF Rx trials
1
9
26
From the FAIR-HF trial: The minimal clinically important difference (MCID) for KCCQ score was ⬇️ than 5-point change for weeks 4 and 24 in HFrEF pts. Imp implications for clinical interpretation of patient reported outcomes and endpoint selection.
0
3
26
🔥article regarding threshold of statistical significance in HF trials and how to interpret/communicate uncertainty within trial results. Published in
@ESC_Journals
@ESCardioNews
@safinmc
@mvaduganathan
@MRMehraMD
@drjohnm
@MarcoMetra
2
6
24
📌 Imp to teach research skills, both theoretical and practical, at grass root level so today’s students can be tomorrows scientist in the developing 🌎
📌Since
@R_C_O_P
, we have taught >3500 students (>70% women and ⬆️ from rural areas), of whom many are now published 📝
(2/3)
4
2
23
Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat Across EF in Victoria Trial
@JavedButler1
@texhern
@JACCJournals
@lamcardio
@DukeHeartCenter
@AdriaanVoors
@coconnormd
@JustinEzekowitz
0
1
23
With 🌍of HF trials, geographical differences in resp to rx are imp. Placebo effect is well knwn-here we show there are country level variation in placebo effect. Need more data for replication-imp aspect for future 🌎 HF trials. Mentored by
@JavedButler1
2
6
22
The pathophysiological link between CKD and CVD is fascinating. Looking forward to this important session at
@CVCTForum
on the rapidly changing landscape of cardiokidney trials. Will be an interesting discussion with the leaders in this space
Register at
0
8
23
📌Such models should be considered in other developing 🌎 to overcome shortage of physcian scientists.
📌Special thanks to
@FrancescoPaneni
for letting us contribute in
@ehj_ed
on this imp topic.
@AnkurKalraMD
@JTLLERGO
@ValleAlfonso
@vbluml
0
2
22
@vkittipibul
giving a masterclass on blood volume analysis in heart failure at TCT
@FudimMarat
@robmentz
@DCRINews
@DukeCardFellows
@DaxorBVA
@BalimSenmanMD
@JasonKatzMD
0
4
21
• Carillon Device Vs GDMT in Patients with Secondary MR and Severe LV Enlargement
• Carillon Device improved MV function, LV morphology, functional outcomes and HFH
• Pre-operative LV dimension should not be a limiting factor for eligibility
0
2
21
PROGRESS-HF Trial Published in the May Issue of
@JCardFail
. Elamipretide did not improve LVESV at 4 weeks in HFrEF patients.
@JavedButler1
@gcfmd
@Filippatos
@AdriaanVoors
@SJGreene_md
@HFSA
@coconnormd
@UMMC_Heart
@UMMCnews
1
5
20
Many thanks Dr Michos
@ErinMichos
for your amazing help and support throughout. Has been such a pleasure collaborating with you.
Wow
@DukeHeartCenter
@manesh_patelMD
chose very well! 👏👏👏 The extraordinary
@ShahzebKhanMD
is going to be a cardiology fellow with
@DukeCardFellows
. It has been a great honor to be one of his collaborators in his journey. Take good care of him
@DukeHFDoc
@robmentz
@SvatiShah
!
1
0
47
0
1
19
📌Effect of
#SGLT2
Inhibitors on Cardiovascular Outcomes Across Various 👥 Population
#CardioTwitter
#CardioEd
#SGLT2i
3
49
138
0
1
14
🔥in
@CircOutcomes
regarding Fragility Index in CV Trials. Statistical sig can change based on few events.Brilliant accompanying editorial by
@ProfDFrancis
.
0
5
14
1
2
14
Excellent paper in
@AnnalsofIM
regarding dual versus triple therapy for Afib after PCI led by
@safinmc
. Accompanying editorial discusses the difference between our and the recent
@ESC_Journals
@ehj_ed
meta analysis.
@ErinMichos
@mmamas1973
Dual Versus Triple Therapy for Atrial Fibrillation | Ann Intern Med | ACP | our latest SRMA in Annals of IM
@ErinMichos
@ShahzebKhanMD
@Osmancardio
@mmamas1973
@RaniKHasan
@DiZhao16
1
1
9
0
4
13
Great article in
@EuroInterventio
@ESCardioNews
led by
@TariqJamalSidd1
@ShariqUsman2
@safinmc
on current risk prediction models after TAVR. Mentored by
@DLBHATTMD
@RamiDoukky
@DesaiMilindY
@AnkurKalraMD
0
5
13
Suggested approach of using SGLT-2 inhibitors or GLP-1 RA in different clinical scenarios
1
4
12
Our latest meta-analysis published in
@asaiojournal
regarding obesity and LVAD outcomes.
@ShariqUsman2
@Mustafa_memon2
@CookCtyHealth
@DemmerRyan
0
4
10
In response to an excellent article by
@rudolf_deboer
et al in JACC showing that CV risk factors are strongly and similarly associated with incident HF in both sexes
@MichaelJBlaha
@JJheart_doc
@JenHoCardiology
1
2
12
How many CV RCTs adhere to CONSORT Abstract guidelines. Check our latest paper in
@CircOutcomes
.
@safinmc
@RamiDoukky
@AsimShaikh99
@rohan_ochani
0
6
10
Excellent accompanying editorial by Drs. Reddy and Borlaug
@MayoClinicCV
. Steps needed to standardize and use these important data.
0
1
10
Our recent meta analysis published in
@CirculationEP
led by
@ZainAsadEP
shows catheter ablation compared with medical therapy reduces mortality, primarily driven by HFrEF. ⬇️age ⬆️benefit from ablation.
@drjohnm
@StavrosStavrak1
0
1
9
Great commentary by
@TCTMD_Caitlin
@TCTMD
on our consort adherence paper in
@CircOutcomes
and spin paper in
@JAMANetworkOpen
@MDaware
.
@drjohnm
@RamiDoukky
@safinmc
@TariqJamalSidd1
@RichKrasuskiMD
@AsimShaikh99
@rohan_ochani
0
6
9
@DLBHATTMD
Thank you
@DLBHATTMD
for all the support and guidance. Honored to co-author this important paper with you.
2
1
10
0
2
9
Thank you
@hmkyale
for highlighting our work regarding spin in
@JAMANetworkOpen
.
@drjohnm
@safinmc
@TariqJamalSidd1
@RamiDoukky
Why you need to critically review studies, not just read abstract conclusion. "This study suggests reports of CVD RCTs w/statistically nonsig 1° outcomes, investigators often manipulate language to detract from neutral primary outcomes.
@JAMANetworkOpen
2
35
69
0
0
6
CHART study led by
@JavedButler1
published in the May Issue of the
@JCardFail
. In HIV pts, diastolic dysfunction associated with ⬇️QOL and multiple alterations in cardiac structure/function
@SJGreene_md
@HFSA
@SvatiShah
@HFpEF
@texhern
@UMMCnews
0
4
8
Excellent initiative by
@BalimSenmanMD
🚀 Calling all
#CCCEnthusiasts
! 🚀
Are you passionate about CCC and eager to connect with others? 🤔Or a trainee trying to navigate training and the world of CCC, we've got the perfect space for you! 🌐
🌟 Introducing – Your One-Stop Shop for CCC! 🌟
2
18
49
0
1
8
Our study published in
@JAMANetworkOpen
discusses level and prevalence of “spin” in CV RCTs with non-sig primary outcomes.
@HarisRiazMD
@TariqJamalSidd1
@safinmc
@RamiDoukky
@drjohnm
1
1
7
Our letter in jacc regarding gender equity trends in academic cardiology
@TariqJamalSidd1
@ShariqUsman2
@JACCJournals
@Cardiotweets83
0
2
6
Our meta-analysis of mendelian randomization studies (first ever) in almost 1 million patients shows that obesity likely has a causal association with coronary artery disease !!
@haithamahmedmd
@HarisRi50354107
@TariqJamalSidd1
1
3
7
📌Weight loss with empa maybe from loss of calories and Na in urine
📌 Slightly ⬆️ weight loss with empa in ⬆️ BMI pts with no significant weight loss in pts with low baseline BMI
@FudimMarat
@UoGHeartFailure
@Sglt2inhibitorL
@DukeHeartCenter
0
2
5
@mmamas1973
@BartoszHudzik
@CMichaelGibson
@DrMarthaGulati
@HeartOTXHeartMD
@HanCardiomd
@hvanspall
@HillLoreena
@ShelleyWood2
@HFA_President
Thanks so much
@mmamas1973
for your kind words
0
0
6
Is intensive lowering of LDL associated with incident DM risk ? Check out our latest paper in
@JAHA_AHA
. Great work by the MA expert
@safinmc
.
@SethShayMartin
@MichaelJBlaha
@adnanalkhouli
@ZainAsadEP
@RamiDoukky
0
1
5
"Performance of Current Risk Models in Predicting Short-Term Mortality After Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis" by
@ShariqUsman2
@TariqJamalSidd1
@ShahzebKhanMD
et al.
#EAPCI
0
8
13
0
2
5
@safinmc
@adnanalkhouli
@claymarsh
@kadiyala2000
@gmarshohiostate
@summerbooks1
@marcogreenberg
@samquinones7
@CourtneySpence
@WVUHeart
@AnkurKalraMD
@RiyazBashir
@FSQMD
@ErinMichos
@HarisRiazMD
@ElianoNavarese
@ZainAsadEP
“Never, never, never give up”- Winston Churchill
0
0
5
In >30% of HF pts, RAASi is stopped/not optimized due to fear of hyperK. In this viewpoint published in EJHF, we discuss the role of novel K binders as enabling therapy in HF patients and point out examples of enabling therapies in medicine
@JavedButler1
0
1
5
"Obesity is not benign" TCTMD covers our recent meta analysis of mendelian randomization studies
@HarisRiazMD
@TariqJamalSidd1
@ShariqUsman2
@haithamahmedmd
@HeartDocSadiya
0
0
5
Balloon atrial septostomy in advanced PAH. Relatively safe and benefical hemodynamic effects. Our paper in
@accpchest
. Will use of BAS become more common ?
@safinmc
@Mustafa_memon2
@SalilDeo
@PulmonaryNews
@HF_Digest
@theheartorg
@Cardiotweet
0
2
5
1
0
4
@djc795
@bnallamo
@CircOutcomes
@venkmurthy
@SVRaoMD
@DrNancySweitzer
@ProfDFrancis
Absolutely. I think its virtually impossible to fit in all the important elements within 200-250 words. Effect of hardwiring abstract reporting elements (like
@AnnalsofIM
) will be interesting as pointed in our discussion.
@safinmc
@RichKrasuskiMD
0
0
3
In this editorial for AJM,
@HarisRiazMD
and I discuss the impact of documenatation on modern medicine
0
3
4
@CardiologyToday
@GoHealio
covers our meta analysis regarding the effect of canagliflozin on BP and weight at 1 year follow up
@TariqJamalSidd1
@ShariqUsman2
@HeartDocSadiya
0
5
4
@drjohnm
@ADAlthousePhD
@WFMMD
Agree. Also FI obv does not solve the larger stats issues like frequentist vs bayesian, using statistical sig threshold or not. However if we c/w using frequentist+statistical sig, I dont see an issue with FI telling us numerically when results can jump
0
0
4
@SJGreene_md
@ESC_Journals
@yreddyhf
@JavedButler1
@MayoClinicCV
@DCRINews
@UMMCMedicine
@abouezzeddine
@ShannonMDunlay
@HFpEF
@DukeHeartCenter
@ValleAlfonso
@MarcoMetra
Many thanks
@SJGreene_md
for letting me contribute to this editorial.
0
0
3
@vbluml
@DukeHeartCenter
@JavedButler1
@SJGreene_md
@FudimMarat
@RichKrasuskiMD
@ErinMichos
@ambarish4786
@RamiDoukky
@DukeCardFellows
Thank you so much
@vbluml
. Thrilled to have the opportunity to work with you and everyone at
@DukeHeartCenter
0
0
3
@SJGreene_md
@DukeCardiology
@DCRINews
@texhern
@robmentz
@_adevore
@manesh_patelMD
@DukeHFDoc
@DukeCardFellows
Thank you so much
@SJGreene_md
. Eagerly look forward to working with everyone at
@DukeCardiology
. So excited !!
0
0
3